GlassScriptPhysician profile
Salman Mandhai
NPI 1639445166
$2,386.17
in general payments reported to CMS, 2019-2025
11 companies · $62.42 in 2025
The $62.42 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $289 · 2021: $74.99 · 2022: $170 · 2023: $219 · 2024: $1,572 · 2025: $62.42.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $996 · Food and Beverage: $839 · Education: $17.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $996.27 |
| Food and Beverage | $839.41 |
| Education | $17.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,520.53 | 2022-2024 | Mitraclip |
| Abiomed | $187.84 | 2024 | Impella |
| Centinel Spine, LLC | $125.00 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.37 | 2023 | Jardiance |
| Boston Scientific Corporation | $112.29 | 2019 | |
| Amgen INC. | $92.83 | 2019-2023 | Repatha |
| Astrazeneca Pharmaceuticals LP | $88.88 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $57.56 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $39.37 | 2023 | Verquvo |
| Impulse Dynamics (USA) INC. | $24.05 | 2025 | Optimizer |
| Pfizer INC. | $14.45 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Salman Mandhai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.